Welcome to the Clinical Trials Office 

As you consider treatment options for yourself or your loved one, you may consider participation in a clinical trial. The resources below provide general and specific information that can help you navigate the clinical trial process.

Current Clinical Trials

Below is a list of enrolling clinical trials at MaineHealth.  Studies can open and close quickly so please contact the Clinical Trials Office directly or speak with your healthcare professional if you are interested in learning more about one of the trials.  You can reach the Clinical Trials Office at 207-396-8670 or email at clinicalresearch@mainehealth.org.

For a complete list of trials open in the U.S. and abroad, visit www.clinicaltrials.gov.

(POTS) Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain Learn more

(Regional BKA) A Prospective, Randomized Trial of Liposomal Bupivacaine Compared to Continuous Nerve Catheters on Pain Control and Post-Operative Opioid Use in Receiving Popliteal Nerve Blocks for Below the Knee Amputation Learn more

(ATHN – Transcends) A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders Learn more

(ATHN 8: PUPs Matter Study) US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia Learn more

(A051701) Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas Learn more

(A011801/ COMPASSHER2) The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib Learn more

(A211801/ BRCA-P) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation Learn more

(A221803) Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial Learn more

(A231901CD/ SharES) Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHADES) Learn more

(CCTG MA.39) TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer Learn more

(A011801/ COMPASSHER2) The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib Learn more

(EA1181/ CompassHER2-pCR) CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Learn more

(NOHA in BRCA) A Pilot Study of NOHA levels in BRCA positive Breast Cancer

(NOHA in TNBC) A Pilot Study of NOHA as a monitoring biomarker in triple negative breast cancer (TNBC)

(ACNS1831) A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Learn more

(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Learn more

(cHOD17) Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 Learn more

(COG AALL1631) International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Learn more

(COG AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly Learn more

(COG AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations Learn more

(COG AAML18P1) Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) Learn more

(COG ACCL20N1CD) Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States Learn more

(COG ACNS1422) A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Learn more

(COG ACNS1831) A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Learn more

(COG ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Learn more

(COG ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Learn more

(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) Learn more

(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy Learn more

(COG ANBL00B1) Neuroblastoma Biology Studies Learn more

(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Learn more

(COG ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) Learn more

(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma Learn more

(COG ANHL1931) A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Learn more

(COG AOST 2031) Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Learn more

(COG APAL2020SC) Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias Learn more

(COG APEC14B1) Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Learn more

(COG AREN03B2) Renal Tumors Classification, Biology, and Banking Study Learn more

(COG AREN1921) Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) Learn more

(COG ARST2031) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS) Learn more

(COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia Learn more

(COG AALL1731) A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Learn more

(COG APEC1621SC/ COG MATCH) COG Pediatric Molecular Analysis for Therapy Choice Screening Protocol Learn more

(TPX-0005) A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, And Anti-Tumor Activity Study Of Repotrectinib In Pediatric And Young Adult Subjects With Advanced Or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations Learn more

(A221805) Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer Learn more

(EA2182/ DECREASE) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Learn more

(NRG-CC005/ FORTE) Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps Learn more

(NRG-GI008/ CIRCULATE) Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Learn more

(A021502/Atomic) Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Learn more

(EA2182/DECREASE) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Learn more

(NRG-GI004) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Learn more

(NRG-GI005/ COBRA) Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) Learn more

(EA2174) A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Learn more

(EA2183) Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Learn more

(EA2186/ GIANT) A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) Learn more

(NRG-GU010/ GUIDANCE) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) Learn more

(NRG-GU012/ SAMURAI) Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) Learn more

(S1600) A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes Learn more

(S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer Learn more

(S1806) Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer Learn more

(GOG-3043/ ROCC) A Phase III Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC) Learn more

(GOG-3049/ UP-NEXT) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). Learn more

(NRG-CC008/ SOROCk) A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers Learn more

(NRG-GY012) A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib/Olaparib and the Combination of Olaparib/Wee1 Inhibitor AZD1775 in Women With Recurrent, Persistent or Metastatic Endometrial Cancer (EEC) Learn more

(NRG-GY019) A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Learn more

(NRG-GY020) A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Learn more

(NRG-GY023) A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Learn more

(NRG- GY026) A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Learn more

(TSR 3000-02-05/ OPAL) Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination-Deficient Stage III/IV Ovarian Cancer Learn more

(A051901) Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma Learn more

(NRG-BN003) Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Learn more

(NRG-BN005) A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas Learn more

(ON-TRK) ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib Learn more

(PROSPECT/ ONO-4059) An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL) Learn more

(TRIDENT/ EF-32) EF-32: Randomized, open-label study of Tumor Treating Fields (Optune®, 200kHz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma Learn more

(10323/ Moonshot BioBank) Cancer Moonshot Biobank Learn more

(A031704/ PDIGREE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Learn more

(A031902) CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer Learn more

(A032001/ MAIN-CAV) MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer Learn more

(A212102) Blinded Reference Set for Multicancer Early Detection Blood Tests Learn more

(A051901) Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma Learn more

(Cardio-Surveillance)  Cardio-surveillance of MHCCN Cancer Patients Undergoing Immune Checkpoint Blockade

(DCP-001) Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

(EA8184/ Green Tea Study) A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers Learn more

(EA8191/ INDICATE) Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence Learn more

(EA8192) A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy Learn more

(NRG-HN005) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Learn more

(KRAS G12C) A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (KRYSTAL-1) Learn more

(NHLBI-MDS) The National Myelodysplastic Syndromes Natural History Study Learn more

(NRG-GU009) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) Learn more

(NRG-HN009) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Learn more

(S1800D) A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study) Learn more

(S1912CD/ CREDIT) A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) Learn more

(SIMPRO) SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice Learn more

(TAPUR) TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Learn more

(WF-1805CD/ HN-STAR) Implementation and Effectiveness Trial of HN-STAR (HN-STAR) Learn more

(WF-1901/ IMPACTS) Internet-delivered Management of Pain Among Cancer Treatment Survivors Learn more

(A081801/ Alchemist Chemo-IO) Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study Learn more

(A082002) A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Learn more

(A151216/Alchemist Screening) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Learn more

(A171901) Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist’s/ Patient’s Choice) Learn more

(E4512/Alchemist Treatment) A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Learn more

(EA5181)Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Learn more

(EA5191) A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC Learn more

(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Learn more

(NIT-119) A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Learn more

(S1827/ MAVERICK) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer Learn more

(CRYPTICS) Randomized Controlled Trial Comparing Dimethyl Sulfoxide Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery Learn more

(PACES) Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG Learn more

(PRIMARY) Percutaneous or Surgical Mitral Valve Repair Learn more

(FINEARTS-HF) A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and
left ventricular ejection fraction =40% (LVEF =40%) Learn more

(Mantra) Corcym Mitral, Aortic aNd Tricuspid post-maRket Study in a reAl-world setting

(Philips Ultrasound) Philips Ultrasound Study Protocol – Maine Medical Center

(REAL AF Registry) Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry Learn more

(TAVR Unload) Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial (TAVR UNLOAD) Learn more

(RECOVER) NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults Learn more

(BOOST3) Brain Oxygen Optimization in Severe Traumatic Brain Injury—Phase 3 Learn more

(COBRE PROTECT) Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT): a randomized-controlled trial and microbiome assessment Learn more

(ICECAP) Influence of Cooling duration on Efficacy in Cardiac Arrest Patients Learn more

(MODERNISE) MOderate vs DEep Regimen in NeuroIntensive Care SEdation Learn more

(PCAS) Inter-individual variables associated with neurological outcomes in Post Cardiac Arrest Syndrome Learn more

(PRECICECAP) A multicenter, observational substudy to the ICECAP trial to define patterns of post-arrest injury (phenotypes) that predict optimal duration of induced hypothermia after cardiac arrest Learn more

(AR-501) A Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citrate), administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis subjects Learn more

(LITE) A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis. Short title: Light Treatment Effectiveness (LITE) Study Learn more

(ED-INNOVATION) Emergency Department-Initiated Buprenorphine Validation Network Trial

 

(ATHN 8: PUPs Matter Study) US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia Learn more

(ATHN 9) A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD) Learn more

(ATHN 10) Leveraging the ATHNdataset to Document the State of Rare Coagulation Disorders in the United States

(ATHN 11) An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia Learn more

(Community Counts) CDC Public Health Surveillance for Bleeding Disorders – Registry for Bleeding Disorders Surveillance

(RECOVER) NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults Learn more

(BN42083) A phase iiib multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis Learn more

(CHARM) Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction Learn more

(EPY) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects with Focal Onset Seizures with Suboptimal Response to Levetiracetam Learn more

(HASH4) Neuroinflammatory Response and Headache Control in Patients after Subarachnoid Hemorrhage (HASH4-CSF)Learn more 

(HEP3) Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy Learn more

(Telemedicine in Neonatal Encephalopathy) Telemedicine to reduce disparities in the identification and treatment of neonatal encephalopathy Learn more

(TEMPO-1) A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Two Fixed Doses Of Tavapadon In Early Parkinson’S Disease (TEMP0-1 Trial) Learn more

(TEMPO-3) A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial To Evaluate The Efficacy, Safety, And Tolerability Of Tavapadon As Adjunctive Therapy For Parkinson’s Disease In Levodopa-Treated Adults With Motor Fluctuations (TEMP0-3 Trial) Learn more

(TEMPO-4)  58-Week Open Label Trial of TAVAPADON In PARKINSON’S Disease (TEMPo-4 TRIAL) Learn more

(XPF-201) A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy Learn more

(CREST 2) Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial Learn more

(CREST-H) Carotid Revascularization and Medical Management for Asymptomatic Carotid stenosis – Hemodynamics (CREST-H) Learn more

(STERLING Registry) A Prospective, Multi-Center, Single Arm Study To Obtain “Real World” Clinical Data And Characterize The Acute And Long-Term Performance Of The Micrusframe And Galaxy Coils For The Endovascular Treatment Of Intracranial Aneurysms Learn more

(AeroFact) A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFactTM (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infants at Risk of Worsening Respiratory Distress Syndrome Learn more

(COMPOSE) A Double-Blind, Randomized, Placebo-Controlled, Phase 1/2 Study To Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Effects On Clinical Outcomes Of Pegtibatinase (TVT-058) Administered Subcutaneously In Subjects With Cystathionine Beta-Synthase-Deficient Homocystinuria Learn more

(CALM 201) A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Dose, 2-Way, 2-Period Crossover Safety and Exploratory Efficacy Study of INP105 (POD-OLZ) for the Acute Treatment of Agitation in Adolescents with Autism Spectrum Disorder Learn more

(Stop/Continue Study) A Prospective, Randomized Trial of the Effect of Buprenorphine Continuation on Pain Control and Post-Operative Opioid Use Learn more

(CREST 2) Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial Learn more

(CREST-H) Carotid Revascularization and Medical Management for Asymptomatic Carotid stenosis – Hemodynamics (CREST-H) Learn more

(Roadster 3) Post-Approval Study Of Transcarotid Artery Revascularization In Standard Risk Patients With Significant Carotid Artery Disease (The Roadster 3 Study) Learn more

(APO Study) Beta 1-Selective Blockade for Prevention of Postmenopausal Bone Loss: A Phase 3, Multi-Center, Double-Blinded, Randomized Placebo-Controlled Trail Learn more

(Estradiol MRG) Initial Evaluation of Safety and Efficacy of Administration of Estradiol by Subcutaneous Injections: A Pilot study in Male-to-Female Transgender Patients

LEARN MORE ABOUT CLINICAL TRIALS

Next Step for Providers

Complete our referral form to connect a patient with our oncology clinical trials program.

Next Step for Patients

Complete our patient referral form to learn more about our clinical trials program.

  The MaineHealth Cancer Care Network was awarded a grant by the National Cancer Institute (NCI), as a member of the NCI Community Oncology Research Program (NCORP), to implement a new cancer research program that aims to reach more Mainers in their own cities and towns, ensuring they have access to the best possible patient care, including access to more advanced clinical trials in their home communities.  If you are a patient and thinking about joining a clinical trial, talk to your doctor first.  If you are a provider and would like more information about NCORP, please contact the Clinical Trials Office (contact information below).

Clinical Trials Office

81 Research Drive
Scarborough, Maine 04074